Nautilus Biotechnology (NAUT) versus Its Peers Head to Head Contrast

Nautilus Biotechnology (NASDAQ:NAUTGet Rating) is one of 43 publicly-traded companies in the “Analytical instruments” industry, but how does it weigh in compared to its competitors? We will compare Nautilus Biotechnology to similar businesses based on the strength of its risk, earnings, dividends, analyst recommendations, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Nautilus Biotechnology and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nautilus Biotechnology 0 2 2 0 2.50
Nautilus Biotechnology Competitors 319 1325 1830 57 2.46

Nautilus Biotechnology presently has a consensus price target of $8.67, suggesting a potential upside of 105.86%. As a group, “Analytical instruments” companies have a potential upside of 31.44%. Given Nautilus Biotechnology’s stronger consensus rating and higher possible upside, equities analysts clearly believe Nautilus Biotechnology is more favorable than its competitors.

Insider and Institutional Ownership

47.9% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 60.0% of shares of all “Analytical instruments” companies are owned by institutional investors. 13.4% of shares of all “Analytical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Nautilus Biotechnology and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Nautilus Biotechnology N/A -$50.31 million -7.39
Nautilus Biotechnology Competitors $1.19 billion $356.47 million -8.39

Nautilus Biotechnology’s competitors have higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


This table compares Nautilus Biotechnology and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nautilus Biotechnology N/A -15.57% -14.77%
Nautilus Biotechnology Competitors -187.73% 3.44% -10.22%


Nautilus Biotechnology competitors beat Nautilus Biotechnology on 8 of the 11 factors compared.

About Nautilus Biotechnology (Get Rating)

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with's FREE daily email newsletter.